| elimination_half-life = 24-36 hours <ref>{{cite journal  |vauthors=Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, etal |title=The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. |pmid=22459616 |doi=10.1093/gerona/gls078 |volume=68 |date=Jan 2013 |journal=J Gerontol A Biol Sci Med Sci |pages=87â€“95 |pmc=4111291}}</ref>

 
In a Phase 1 clinical trial of 76 adult male humans in which the dose size was varied, a dose-dependent increase in lean body mass was observed with no significant adverse events over 21 days.<ref name=":1">Basaria, S., L. Collins, E. L. Dillon, K. Orwoll, T. W. Storer, R. Miciek, J. Ulloor, A. Zhang, R. Eder, H. Zientek, G. Gordon, S. Kazmi, M. Sheffield-Moore, and S. Bhasin. "The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men." The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 68.1 (2012): 87-95. Web. 21 Nov. 2016.</ref>
